Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "The Factors Influencing Depression Endpoints Research (FINDER) study: final results of Italian patients with depressio"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: The Factors Influencing Depression Endpoints Research (FINDER) study: final results of Italian patients with depression. | Caruso et al. Annals of General Psychiatry 2010 9 33 http www.annals-general-psychiatry.eom content 9 1 33 ANNALS OF GENERAL PSYCHIATRY PRIMARY RESEARCH Open Access The Factors Influencing Depression Endpoints Research FINDER study final results of Italian patients with depression D I s z t S-. I s n ri I r 1 A I ro s D r r I 2 A I r r D r r 2 f L wx I I s I 12 I I 11 z I rd r s r r I 1 4 Rosangela Caruso Andrea Rossi Alessandra Barraco ueboran Quail Luigi Grassi Italian FINDER study group1 Abstract Background Factors Influencing Depression Endpoints Research FINDER is a 6-month prospective observational study carried out in 12 European countries aimed at investigating health-related quality of life HRQoL in outpatients receiving treatment for a first or new depressive episode. The Italian HRQoL data at 6 months is described in this report and the factors associated with HRQoL changes were determined. Methods Data were collected at baseline 3 and 6 months of treatment. HRQoL was measured using components of the 36-item Short Form Health Survey SF-36 mental component summary MCS physical component summary PCS and the European Quality of Life-5 Dimensions EQ-5D visual analogue scale VAS and health status index HSI . The Hospital Anxiety and Depression Scale HADS was adopted to evaluate depressive symptoms while somatic and painful physical symptoms were assessed by using the 28-item Somatic Symptom Inventory SSI-28 and a VAS. Results Of the initial 513 patients 472 completed the 3-month observation and 466 the 6-month observation. The SF-36 and EQ-5D mean SD scores showed HRQoL improvements at 3 months and a further smaller improvement at 6 months with the most positive effects for SF-36 MCS baseline 22.0 9.2 3 months 34.6 10.0 6 months 39.3 9.5 and EQ-5D HSI baseline 0.4 0.3 3 months 0.7 0.3 6 months 0.7 0.2 . Depression and anxiety symptoms HADS-D mean at baseline 13.3 4.2 HADS-A mean at baseline 12.2 3.9 consistently decreased during the first 3 months 8.7 4.3 7.5